There are currently 2781 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center and Brigham and Women's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410
Recruiting
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
06/18/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Pulmonary Arterial Hypertension
Register for Updates
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
NCT06144632
Recruiting
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Massachusetts General, Boston, Massachusetts
Conditions: Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
NCT03191149
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +3 locations
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Register for Updates
SELUTION SLR™ 014 In-stent Restenosis
NCT04280029
Recruiting
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Coronary Restenosis
Register for Updates
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
NCT04500665
Recruiting
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
06/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Chronic Kidney Diseases
Register for Updates
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781
Recruiting
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma
Register for Updates
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
NCT06144840
Recruiting
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
06/18/2024
Locations: MGH, Boston, Massachusetts
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Boston, Massachusetts +1 locations
Conditions: Neoplasms
Register for Updates
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Floating Hospital For Children at Tufts Medical Center, Boston, Massachusetts
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Register for Updates
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182
Recruiting
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
06/18/2024
Locations: Harvard Medical School - Boston Children's Hospital, Boston, Massachusetts
Conditions: Arthritis, Juvenile
Register for Updates
Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)
NCT05238116
Recruiting
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Clinical Research Site 025, Boston, Massachusetts
Conditions: Refractory IPA
Register for Updates
A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
NCT05379634
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Nipocalimab versus placebo in participants with active idiopathic inflammatory myopathies (IIM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: The Brigham and Women's Hospital, Inc., Boston, Massachusetts
Conditions: Myositis
Register for Updates